NERLYNX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NERLYNX (NERLYNX).
Neratinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor that inhibits EGFR, HER2, and HER4, leading to reduced downstream signaling and cell proliferation.
| Metabolism | Primarily metabolized by CYP3A4; also a substrate of P-glycoprotein (P-gp). |
| Excretion | Primarily hepatic metabolism; 97% of dose recovered in feces (including unchanged drug and metabolites), <1% in urine as unchanged drug. Biliary excretion is a major route. |
| Half-life | Terminal half-life approximately 7–17 days (mean ~9 days) after a 240 mg daily dose, supporting once-daily dosing. Steady state reached by ~4–6 weeks. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin and α1-acid glycoprotein. |
| Volume of Distribution | Mean Vd/F ~ 2,340 L (range 1,190–8,510 L) after oral administration, indicating extensive distribution into tissues (Vd > total body water). Not routinely expressed per kg. |
| Bioavailability | Oral bioavailability is low (~30%) due to extensive first-pass metabolism. Absolute bioavailability not established in humans; relative bioavailability compared to oral solution is 100%. |
| Onset of Action | Not applicable for oral tablet; clinical effect (tumor response) typically assessed after ≥8 weeks of continuous dosing. |
| Duration of Action | Prolonged due to long half-life; drug remains at therapeutic levels for several weeks after discontinuation. Continued inhibition of HER2 signaling persists while drug is present. |
| Molecular Weight | 557.04 |
NERLYNX (neratinib) 240 mg (6 tablets of 40 mg) orally once daily with food for a total duration of 1 year.
| Dosage form | TABLET |
| Renal impairment | For severe renal impairment (CrCl 30-89 mL/min), no dose adjustment is required. For end-stage renal disease (CrCl <30 mL/min), no data available; use with caution. |
| Liver impairment | For mild hepatic impairment (Child-Pugh A), no dose adjustment. For moderate (Child-Pugh B), reduce dose to 120 mg (3 tablets) once daily. For severe (Child-Pugh C), reduce dose to 80 mg (2 tablets) once daily. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no recommended dosing. |
| Geriatric use | No specific dose adjustment based on age alone; monitor renal and hepatic function due to potential age-related decline. |
| 1st trimester | Avoid use; based on animal data, may cause fetal harm. There are no adequate well-controlled studies in pregnant women. |
| 2nd trimester | Avoid use; can cause fetal harm when administered to a pregnant woman, as it inhibits HER2 signaling which is implicated in cardiac and neural development. |
| 3rd trimester | Avoid use; risk of oligohydramnios and fetal renal impairment due to potential effects on EGFR signaling. |
Clinical note
Comprehensive clinical and safety monograph for NERLYNX (NERLYNX).
| Placental transfer | Based on animal studies, neratinib crosses the placenta and is embryotoxic and fetotoxic. Human data are absent, but the drug is expected to cross the placental barrier given its low molecular weight. |
| Breastfeeding | It is not known whether neratinib is excreted in human milk; however, many drugs are excreted in human milk and there is potential for serious adverse reactions in nursing infants. Women should discontinue breastfeeding during treatment and for at least 1 month after the last dose. |
■ FDA Black Box Warning
Nerlynx can cause severe and life-threatening diarrhea. Monitor and manage diarrhea aggressively. If diarrhea is not adequately managed, interrupt or dose reduce Nerlynx.
| Serious Effects |
Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole)Known severe hypersensitivity to neratinib or any excipients
| Precautions | Diarrhea: Severe and life-threatening; monitor and manage aggressively., Hepatotoxicity: Elevated transaminases and bilirubin; monitor liver function tests., Embryo-fetal toxicity: Can cause fetal harm; advise females of reproductive potential of effective contraception. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they increase neratinib exposure. Administer with food to improve tolerability. |
Loading safety data…
| Lactation Rating | L5 |
| Teratogenic Risk | Based on its mechanism of action as a tyrosine kinase inhibitor and animal studies, NERLYNX (neratinib) is expected to cause fetal harm when administered to pregnant women. In animal reproduction studies, neratinib was embryotoxic and fetotoxic at maternal exposures below the recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy should be avoided; if used, the patient should be apprised of the potential hazard to the fetus. First trimester: Highest risk of major congenital malformations. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and potential fetal/neonatal toxicity. |
| Fetal Monitoring | Monitor maternal liver function tests (ALT, AST, bilirubin) monthly during treatment due to risk of hepatotoxicity. Monitor for diarrhea and manage aggressively with antidiarrheals and hydration. Fetal monitoring: Perform ultrasound assessment of fetal growth and amniotic fluid volume if pregnancy occurs during treatment. Monitor for signs of fetal distress if used inadvertently. |
| Fertility Effects | Based on animal studies, NERLYNX may impair female fertility. In female rats, neratinib caused prolonged estrus cycles and reduced fertility at doses below the clinical exposure. Reversibility of effects was not assessed. The effect on male fertility is unknown. Human data on fertility are lacking. |
| Clinical Pearls | NERLYNX (neratinib) is an irreversible pan-HER tyrosine kinase inhibitor approved for extended adjuvant treatment of early-stage HER2-positive breast cancer. It is associated with high incidence of diarrhea; prophylactic loperamide and dose escalation are recommended. Avoid concurrent use with strong CYP3A4 inhibitors or inducers. Monitor for hepatotoxicity. Can cause prolongation of QT interval; avoid use in patients with baseline QTc > 450 msec. |
| Patient Advice | Take with food to reduce gastrointestinal side effects. · Anticipate diarrhea which may be severe; start loperamide prophylactically and continue as needed. · Avoid grapefruit and grapefruit juice during treatment. · Notify your doctor immediately if you experience symptoms of liver problems (yellowing of skin/eyes, dark urine, abdominal pain). · Use effective contraception if you are of childbearing potential. |